Haemonetics Corporation (HAE)

NYSE
Currency in USD
71.36
-0.15(-0.21%)
Closed·
After Hours
71.360.00(0.00%)
·
HAE Scorecard
Full Analysis
Management has been aggressively buying back shares
HAE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
70.5072.16
52 wk Range
55.3094.99
Key Statistics
Edit
Prev. Close
71.36
Open
71.36
Day's Range
70.5-72.16
52 wk Range
55.3-94.99
Volume
368.56K
Average Vol. (3m)
636.27K
1-Year Change
-16.96%
Book Value / Share
16.34
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HAE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
91.10
Upside
+27.66%
Members' Sentiments
Bearish
Bullish
ProTips
8 analysts have revised their earnings downwards for the upcoming period

Haemonetics Corporation News & Analysis

Show more

Haemonetics Corporation Company Profile

Haemonetics Corporation, a medical technology company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tool. It also provides treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient’s overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE closure products comprising VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, clinical specialists, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Haemonetics Corporation Earnings Call Summary for Q4/2025

  • Haemonetics Q4 2025 adjusted EPS of $1.24 beat $1.22 forecast; revenue of $331M slightly exceeded expectations
  • Stock rose 3.66% post-earnings; company reported 4% YoY revenue growth to $1.4B, with 8% organic growth excluding divestitures
  • Adjusted gross margin improved to 60.2%, up 620 bps YoY; company executed $150M share buyback program
  • FY2026 guidance: 3-6% revenue decline on reported basis; organic growth 6-9% excluding CSL; adjusted EPS $4.70-$5.00
  • CEO highlighted strategic execution; 85% of revenue now from high-growth, high-margin products driving profitability
Last Updated: 05/08/2025, 09:46 AM
Read Full Transcript

Compare HAE to Peers and Sector

Metrics to compare
HAE
Peers
Sector
Relationship
P/E Ratio
20.4x−1.7x−0.5x
PEG Ratio
0.46−0.080.00
Price / Book
4.2x4.0x2.6x
Price / LTM Sales
2.5x1.0x3.1x
Upside (Analyst Target)
29.4%137.8%48.3%
Fair Value Upside
Unlock1.2%7.6%Unlock

Analyst Ratings

8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 91.10
(+27.66% Upside)

Earnings

Latest Release
May 08, 2025
EPS / Forecast
1.24 / 1.22
Revenue / Forecast
331.00M / 330.66M
EPS Revisions
Last 90 days

HAE Income Statement

People Also Watch

252.21
RMD
+0.34%
93.26
ZBH
-1.04%
349.57
WAT
+1.02%
57.15
HIMS
-0.71%

FAQ

What Is the Haemonetics (HAE) Stock Price Today?

The Haemonetics stock price today is 71.36

What Stock Exchange Does Haemonetics Trade On?

Haemonetics is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Haemonetics?

The stock symbol for Haemonetics is "HAE."

What Is the Haemonetics Market Cap?

As of today, Haemonetics market cap is 3.43B.

What Is Haemonetics's Earnings Per Share (TTM)?

The Haemonetics EPS (TTM) is 3.33.

When Is the Next Haemonetics Earnings Date?

Haemonetics will release its next earnings report on Aug 12, 2025.

From a Technical Analysis Perspective, Is HAE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Haemonetics Stock Split?

Haemonetics has split 2 times.

How Many Employees Does Haemonetics Have?

Haemonetics has 3023 employees.

What is the current trading status of Haemonetics (HAE)?

As of Jun 13, 2025, Haemonetics (HAE) is trading at a price of 71.36, with a previous close of 71.36. The stock has fluctuated within a day range of 70.50 to 72.16, while its 52-week range spans from 55.30 to 94.99.

What Is Haemonetics (HAE) Price Target According to Analysts?

The average 12-month price target for Haemonetics is USD91.1, with a high estimate of USD108 and a low estimate of USD68. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +27.66% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.